Adult Psychiatry Department of Nîmes University Hospital, 585 chemin du Mas de Lauze, 30900, Nîmes, France.
Centre de Biochimie Structurale (CBS), UMR 5048, University of Montpellier, INSERM U1054, CNRS, Montpellier, France.
Curr Psychiatry Rep. 2022 Oct;24(10):573-581. doi: 10.1007/s11920-022-01361-0. Epub 2022 Aug 12.
We aim to provide an overview of the current state of knowledge about the efficacy of psilocybin in the treatment of depression, as well as its mechanisms of action.
Psilocybin has a large, rapid, and persistent clinical effect in the treatment of resistant or end-of-life depression. Tolerance is good, with mild side effects limited to a few hours after dosing. The studies conducted to date have had small sample sizes. One clinical trial has been conducted against a reference treatment (escitalopram) without showing a significant superiority of psilocybin in the main outcome. The neurobiological mechanisms, mostly unknown, differ from those of SSRI antidepressants. Psilocybin represents a promising alternative in the treatment of depression. Further research with larger sample sizes, particularly against reference treatments, is needed to better understand the neurobiological factors of its effects and to investigate its potential for use in everyday practice.
本次综述旨在概述目前关于迷幻蘑菇素治疗抑郁症的疗效,以及其作用机制的知识现状。
迷幻蘑菇素有很大、很快且持久的临床疗效,可用于治疗难治性或临终期抑郁症。其耐受性良好,仅有轻度副作用,且仅在给药后数小时内出现。迄今为止开展的研究样本量较小。一项针对参照治疗(依地普仑)的临床试验并未显示迷幻蘑菇素有显著优势。其神经生物学机制大部分未知,与 SSRI 类抗抑郁药不同。迷幻蘑菇素在抑郁症的治疗中代表了一种很有前途的替代方法。需要进一步开展样本量更大的研究,特别是针对参照治疗的研究,以便更好地了解其作用的神经生物学因素,并研究其在日常实践中的应用潜力。